Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer: the active molecule — semaglutide — can be the same, but Wegovy (Novo Nordisk) is an FDA‑approved, factory‑made product with validated dosing, purity, sterility, labeled indications and safety data for weight management. Compounded semaglutide is made by pharmacies to order and carries greater uncertainty about strength, purity, sterility, labeling, legal/regulatory oversight, and proven clinical outcomes.

Key differences

• Regulatory status and evidence

  • Wegovy: FDA‑approved for chronic weight management based on large randomized trials showing efficacy and known safety profile.
  • Compounded semaglutide: not FDA‑approved as a finished product for weight loss. No large controlled studies proving the safety or effectiveness of a particular compounded preparation.

• Quality, potency and sterility

  • Wegovy: manufactured under strict GMP controls, batch testing, lot traceability.
  • Compounded: quality depends on the pharmacy. Errors in concentration, contamination, or incorrect formulation have occurred with compounded injectables.

• Formulation and delivery

  • Wegovy: supplied in calibrated, single‑use pens with precise dose increments and a manufacturer‑documented titration schedule.
  • Compounded versions may come in vials or prefilled syringes, may use different excipients/preservatives, and can make accurate dosing and injection technique more variable.

• Safety monitoring and adverse‑event reporting

  • Wegovy: post‑marketing surveillance and formal pharmacovigilance by the manufacturer and FDA.
  • Compounded: adverse events are harder to track to a specific batch, and oversight is mostly at the state level (unless made by an FDA‑registered outsourcing facility).

• Indication, labeling and legalities

  • Wegovy: labeled specifically for weight management; prescribers and insurers follow that label.
  • Compounded semaglutide may be used off‑label and is less likely to be covered by insurance; federal and state regulators have issued warnings about some compounded semaglutide operations, especially foreign or internet sellers.

• Cost and access

  • Wegovy: often expensive but may have manufacturer programs (Novo Nordisk savings/care programs) and sometimes insurance coverage with prior authorization.
  • Compounded: often cheaper out‑of‑pocket but carries the trade‑offs above.

What that means for you

• If you want predictable dosing, the safety record from clinical trials, and regulatory quality control, Wegovy (Novo Nordisk) is the safer/clearer choice.
• If cost or availability is a barrier and you consider compounded semaglutide, only use a U.S. state‑licensed compounding pharmacy (preferably PCAB‑accredited or an FDA‑registered outsourcing facility). Ask the pharmacy for a certificate of analysis, sterility testing, lot information, and clear instructions for storage/use. Discuss risks with your prescriber.

Other named options to consider

• Ozempic (Novo Nordisk): same active drug (semaglutide) but approved for type 2 diabetes at different dosing; sometimes used off‑label for weight loss.
• Mounjaro (tirzepatide, Eli Lilly): a different drug with strong weight‑loss data — ask your clinician if this is appropriate.

If you want, I can:

• List questions to ask a compounding pharmacy (e.g., sterility testing, lot testing, source of API).
• Summarize the Wegovy clinical trial results or outline typical titration and injection steps.